Retatrutide is an investigational peptide that has attracted significant scientific attention because of its interaction with three hormone receptors involved in metabolic regulation.
Unlike compounds that activate a single receptor pathway, retatrutide is designed to activate receptors associated with glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon.
This triple-receptor activity has made retatrutide an important subject of research involving glucose metabolism, energy balance, and metabolic signaling.
Researchers are investigating how these pathways interact and whether simultaneous receptor activation produces different biological responses compared with single- or dual-receptor agonists.
This article explores retatrutide’s molecular characteristics, mechanisms of action, clinical research findings, and ongoing scientific investigations.
Retatrutide, also known by its development code LY3437943, is a synthetic peptide being developed by Eli Lilly.
It belongs to a class of investigational compounds known as triple hormone receptor agonists.
An agonist is a molecule that binds to a receptor and activates a biological response.
Retatrutide is designed to activate three distinct hormone receptors:
Each receptor participates in metabolic regulation through different biological mechanisms.
By acti
